Get The Free Sample Complete
SWOT & PESTLE Analysis Report
This report is shared in order to give you an idea of what the complete SWOT & PESTLE analysis report will cover after purchase. We invest deep in order to bring you insightful research which can add tangible value to your business or academic goals, at such affordable pricing.
Get this report delivered straight into your email inbox for free. You also agree to receive email updates from us on our new reports and solutions.
Get Your Free Summary Copy of the
SWOT & PESTLE Analysis Report
Get the summary SWOT & PESTLE.com report delivered straight to your email inbox for free. Our insightful and holistic reports have helped corporates, academia and researchers take their research forward. You also agree to receive email updates from us on our new reports and solutions.

Elekta SWOT & PESTLE Analysis

ID : 52818153| Dec 2020| 15 pages

COMPANY PROFILE -Elekta

Business Sector :Healthcare

Operating Geography :Sweden, Europe, Global

About Elekta :

Elekta is a Swedish human care company which develops and sells clinical solutions for the treatment of cancer and brain disorder. It was founded in 1972, headquartered in Stockholm, Sweden. It provides radiation therapy, radiosurgery, related equipment and clinical management for treating cancer and brain disorders. Elekta was jointly founded by the late Lars Leksell, Professor of Neurosurgery at the Karolinska Institute in Stockholm, Sweden and his son Laurent Leksell. The organisation was founded in order to commercialize the development of the Leksell Stereotactic System, and Gamma Knife.
Elekta’s products are mainly divided into four areas, which include Elekta Neuroscience, this area deals in developing solutions for the diagnosis and treatment of neurological diseases. The second area, Elekta Oncology, creates clinical solutions for radiation therapy, which include linear accelerators, integrated imaging systems and clinical solutions for patient positioning and immobilization. Elekta Brachytherapy, is the third area, and is engaged in the treatment of cancer through internal radiation. While the fourth one is the Elekta Software, which develops software solutions for patient information, workflow management along with the treatment planning in oncology. Elekta has been a veteran in precision radiation medicine for almost five decades. It employs more than 4,000 employees worldwide, who are committed to ensure that everyone with cancer in the world has access to more precise and personalized radiotherapy treatments. Elekta Unity was chosen as a silver winner for 2020 Edison Awards, while in the 2020 Best in KLAS, Elekta Versa HD ranked first in the Radiation Therapy category. It also won the Innovation Award at the 2019 Swedish Business in Australia Awards, which was sponsored by the Swedish Australian Chamber of Commerce (SACC).
Elekta’s Unique Selling Proposition or USP lies in it being a world-leading provider of cancer management solutions, while offering high quality cancer care with high-end precision, and is cost-effective and efficient with personalized treatments. It also includes image guided radiation therapy, stereotactic radiotherapy and radiosurgery and advanced software systems, throughout the world. Elekta’s mission statement reads “Elekta’s aim is to continue to develop our dialog with stakeholders in a respectful manner. Our ability to operate a responsible business is directly related to creating a strong, reputable brand that supports a long-term sustainable market presence and growth.

Elekta Revenue :


SEK 14,601 million - FY ending 30th April 2020 (y-o-y growth 7.72%)
SEK 13,555 million - FY ending 30th April 2019

Competitive Analysis of Elekta

SWOT
PESTLE
The SWOT analysis of Elekta is presented below:
Strengths
Weaknesses
1. Global leader in radiotherapy solutions
2. Focus on innovation in Precision Radiation Medicine
3. Strategic acquisitions to boost company’s oncology informatics and digital strategy
4. Ranked among world’s most ethical companies for second year in a row
5. Consistently strong financial performance
-- no data found --
Opportunities
Threats
1. Growing demand for radiotherapy and Cancer care worldwide
2. Increasing cancer cases worldwide leading to a shortage of more than 10,000 linacs globally
3. Demographics and increasing incidence
4. Digitalization to improve oncological health care
5. Shift towards Big Data and cloud computing to drive subscription services
1. Vulnerable to cyber and security threats
2. Potential exposure to political and economic risk on a global scale
SWOT & PESTLE (combined)
Complete Report
USD 12.53
*
  • with PayPal
  • with Debit/Credit card
Great quality, Affordable pricing.
Safe and secure payments
On purchase, the report will reach your email inbox within minutes. At rare times, a slight delay not exceeding 4 hours might be caused.

Detailed SWOT Analysis of Elekta

 

Strength

1. Global leader in radiotherapy solutions: Founded in 1972 by Prof. Lars Leksell, Elekta has pioneered the precision radiation therapy for almost five decades now. It has a massive 35% overall market share of the global radiation therapy market. It has presence in more than 30 countries and is the top-of the water name in the country of operation. Geography wise, it has a market share of 21% in North and South America; 43% market share in Europe, Middle East and Africa and 40% market share in Asia Pacific as of 2019. The Europe, Middle East and Africa market region attracts the most sales to the firm by contributing 38% to total net sales. The other two regions, American market and Asia Pacific market, contribute 31% each to total net sales of Elekta.

2. Focus on innovation in Precision Radiation Medicine: Elekta has constantly strived to make patients’ lives better working along with prominent researchers and clinicians. On a mission to fight cancer, it recently launched innovative products in its Neuro and Brachy businesses. In February, 2020 Elekta launched the first Linac (linear accelerator) in Rwanda to make radiotherapy accessible to the public. Innovation in Elekta’s Oncology Information Systems – OIS – are using AI and big data techniques to analyze data from clinics and optimizing their functioning, enhancing results, productivity and finances. These technologies also help in reducing unplanned downtime, thus catering to more patients. It has introduced breakthrough products in the market which have been adopted as market standards such as multi-leaf collimator, image-guided radiotherapy and volumetric modulated arc therapy. Elekta Unity brings another development in radiotherapy by combining a Linac with diagnostics graded MRI.

The remaining section of “Strength” is available only in the 'Complete Report' on purchase.

Weakness

This section is available only in the 'Complete Report' on purchase.

Opportunity

This section is available only in the 'Complete Report' on purchase.

Threat

This section is available only in the 'Complete Report' on purchase.

Major Competitors :

  • Varian Medical Systems
  • Accuray
  • Bebig
  • VewRay
  • Raysearch
  • Philips
SWOT & PESTLE (combined)
Complete Report
USD 12.53
*
  • with PayPal
  • with Debit/Credit card
Great quality, Affordable pricing.
Safe and secure payments
On purchase, the report will reach your email inbox within minutes. At rare times, a slight delay not exceeding 4 hours might be caused.

Check Out Analysis of Other Relevant Companies

TABLE OF CONTENTS
DELIVERY AND FORMAT
WHY CHOOSE US?
References used in Elekta Analysis Report

1. Elekta Annual report 2019 - https://www.elekta.com/investors/fileadmin/reports/annual-reports/Elekta_Annual_Report_2019_20.pdf

2. Elekta investor presentation 2020 - https://www.elekta.com/investors/fileadmin/presentations/2020-21/2020-21-q1-presentation-final.pdf

3. Elekta company website - https://www.elekta.com/company/

4. Elekta company profile- https://in.reuters.com/finance/stocks/company-profile/EKTAb.ST

The detailed complete set of references are available on request in the 'Complete report' on purchase.

How to Reference This Page?

You can use the following in your reference section in order to give credit to the source. For different referencing styles and detailed guidelines, please click here.

Elekta SWOT & PESTLE Analysis - SWOT & PESTLE.COM

SWOT & PESTLE.com (2021). Elekta SWOT & PESTLE Analysis - SWOT & PESTLE.com. [online] Available at: https://www.swotandpestle.com/elekta/ [Accessed 17 Jan, 2021].

In-text: (SWOT & PESTLE.com, 2021)

Copyrights and Disclaimer

Elekta SWOT and PESTLE analysis has been conducted by Ayushi Verma and reviewed by senior analysts from Barakaat Consulting.

Copyright of Elekta SWOT and PESTLE Analysis is the property of Barakaat Consulting. Please refer to the Terms and Conditions and Disclaimer for usage guidelines.

You might also like to check out :
Elekta SWOT & PESTLE Analysis
Price : USD 12.53
Open chat
1
Hello
How can I Help You?